WVE-N531 Shows Sustained Dystrophin Production in Phase 2 Trial of Duchenne Muscular Dystrophy

Investigational exon-skipping therapy WVE-N531 (Wave Life Sciences) demonstrated sustained dystrophin production and early signals of functional benefit in boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping, according to 48-week data from the phase 2 FORWARD-53 trial.

Presented at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, held March 8-11, in Orlando, Florida, the open-label study found that treatment with the stereopure antisense oligonucleotide was associated with increases in dystrophin expression, reductions in biomarkers of muscle damage and inflammation, and improvements in selected functional measures.¹

DMD is a progressive X-linked neuromuscular disorder caused by mutations in the dystrophin gene that result in absence or severe reduction of functional dystrophin protein. Loss of dystrophin leads to muscle fiber degeneration, progressive weakness, and cardiopulmonary complications that typically shorten life expectancy. Therapeutic strategies aimed at restoring dystrophin production, including exon-skipping antisense oligonucleotides, have emerged as disease-modifying approaches for genetically defined subsets of patients.²

FORWARD-53 Trial Overview and Key Findings

Led by Li Tai, MD, PhD, executive director at Wave Life Sciences, the ongoing study enrolled 11 participants (10 ambulatory and 1 nonambulatory) aged 5 to 11 years with DMD amenable to exon 53 skipping. Participants initially received WVE-N531 at 10 mg/kg administered every other week, and all entered the study’s extension phase and transitioned to monthly dosing.

After 48 weeks of treatment, investigators reported that WVE-N531 was generally well tolerated. All treatment-related adverse events were mild to moderate in severity, and no serious adverse events or treatment discontinuations were observed during the study period.

Biochemical analyses demonstrated sustained dystrophin restoration over time. Muscle content–adjusted dystrophin expression measured by western blot averaged 7.8% and appeared to stabilize between weeks 24 and 48. Among the 8 participants evaluated during that interval, 7 (88%) achieved more than 5% mean dystrophin expression. Exon skipping levels, measured using reverse transcription–polymerase chain reaction (RT-PCR), remained consistent through 48 weeks, averaging 54% between weeks 24 and 48. Overall, these findings suggested sustained molecular engagement of the exon-skipping mechanism.

Investigators also reported histologic improvements in muscle tissue. Biopsy analyses showed a transition from regenerative to more mature muscle fibers over time. Between weeks 24 and 48, muscle fibrosis declined by 28.6% (P < .01), while median scores for muscle necrosis and inflammation decreased from 2 to 1, corresponding to minimal tissue damage.

Biomarkers associated with muscle injury and inflammation were also reduced. Notably, creatine kinase levels declined by approximately 50% (P < .001), and reductions in inflammatory markers interleukin-6 and monocyte chemoattractant protein-1 were observed during treatment.

Functional outcomes were assessed using multiple measures. The time-to-rise test demonstrated a mean improvement of 3.8 seconds on the investigational agent relative to natural history data, exceeding the minimal clinically important difference threshold of 1.4 seconds (P < .05). Investigators also reported improvements compared with natural history trajectories on the North Star Ambulatory Assessment as well as increases in handgrip strength from baseline.¹

Drug Background and Mechanistic Approach

WVE-N531 is an investigational stereopure antisense oligonucleotide designed to induce skipping of exon 53 in the dystrophin transcript, enabling production of a shorter but partially functional dystrophin protein. Unlike earlier exon-skipping therapies, WVE-N531 incorporates phosphoryl guanidine (PN) chemistry, which is intended to enhance molecular stability and tissue uptake.

According to investigators, the therapy appears to target both differentiated muscle fibers and muscle stem cells. Engagement of muscle stem cells could theoretically support long-term regenerative capacity, though the functional implications of this mechanism remain to be fully characterized in clinical studies.²

Interpretation and Remaining Questions

Although the findings provide encouraging molecular and histologic signals, several limitations warrant consideration. The FORWARD-53 trial is a small open-label study with only 11 participants and lacked a randomized control group. Comparisons to natural history data may provide context but cannot fully account for variability in disease progression.

Additionally, while increases in dystrophin expression and improvements in biomarkers may suggest biological activity, the relationship between dystrophin levels and long-term clinical outcomes in DMD remains incompletely defined. Larger controlled studies will be necessary to determine whether WVE-N531 can produce durable functional benefits and how it compares with currently available exon-skipping therapies targeting exon 53.

REFERENCES
1. Tai L, Servais L, Bader M, et al. 48-Week Data from the Phase 2 Open-Label FORWARD-53 Study of WVE-N531 in Boys with Duchenne Muscular Dystrophy amenable to Exon 53 Skipping. Presented at: 2026 Duchenne Muscular Dystrophy Clinical & Scientific Conference; March 8, 2026; Orlando, Florida.
2. Aartsma-Rus A, Krieg AM. FDA approval of eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen saga. Nucleic Acid Ther. 2017;27(1):1-3.